Biota Holdings (BTA) company profile

Biota Holdings was an Australian biotechnology company renowned for its pioneering work in antiviral drug discovery, particularly the development of zanamivir, which became the influenza drug Relenza. The company's business model focused on identifying and developing novel drug candidates, primarily in the antiviral space, and then out-licensing them to larger pharmaceutical partners for commercialization. Biota played a significant role in the global fight against influenza through its innovative research.